Leading bone health experts have released a guide to help healthcare providers make proper adjustments to certain osteoporosis medication regimens for patients scheduled to receive a COVID-19 vaccination.
There is no evidence that any osteoporosis therapy affects the risk or severity of COVID-19 infection, alters the disease course or interferes with the efficacy or side effect profile of COVID-19 vaccination, said the authors, a group of organizations that include the American Society for Bone and Mineral Research and the National Osteoporosis Foundation. But vaccinations may need to be prioritized in medication scheduling, requiring alterations to normal regimens to ensure drug effectiveness and safety, they said.
For example, a one-week (minimum of four days) interval is recommended between intravenous bisphosphonate infusion and COVID-19 vaccination. This delay allows clinicians to distinguish between autoimmune or inflammatory reactions resulting from either the IV bisphosphonate administration or COVID-19 vaccination.
The guide also covers the following drugs:
- Oral bisphosphonates
- Denosumab (Prolia)
- Teriparatide (Forteo) or abaloparatide (Tymlos)
- Romosozumab (Evenity)
- Raloxifene
The detailed document with supporting evidence is available available here.
